Loading news...
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price target of $20.
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.
Pfizer Inc. delivered a 17% total return since early November, but I remain cautious. I do not recommend buying PFE stock, as the recent rally is not supported by fundamentals. Valuation analysis and mitigating factors do not justify a bullish stance on PFE.
Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically sig.
Assetmark Inc. grew its position in Pfizer Inc. (NYSE: PFE) by 8.7% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,428,467 shares of the biopharmaceutical company's stock after purchasing an additional 193,859 shares during the quarter. Assetmark Inc.'s holdings in
Pfizer is testing a long-acting GLP-1 weight loss drug and seeing solid results. The company will report on trial results in June, and investors will be watching.
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing for the f
Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the "buy the rumor, sell the news" cliche came in fast and strong, quickly turning the rally into... Here Are Thursday's Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More.
Pfizer remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. PFE's non-COVID portfolio posted 6% operational growth in 2025, with international markets and Pfizer CentreOne driving resilience. Productivity initiatives are on track to deliver $7.2B in net cost savings, supporting margin improvement despite patent cliff and pricing headwinds.
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Pfizer continues to lag the market due to poor financial results and upcoming challenges. However, the company is entering an important period in its clinical development.
Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.
Choosing the right investment vehicles can ensure steady income and wealth generation.
PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.
Pfizer (PFE) is confronting challenges. Even the most prominent companies are not beyond reach.
Advisors Asset Management Inc. lifted its stake in shares of Pfizer Inc. (NYSE: PFE) by 4.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 868,327 shares of the biopharmaceutical company's stock after buying an additional 39,989 shares during the quarter. Advisors
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.